Evidence map›Paper›PMID 41685165›Full record

ReviewActa pharmaceutica Sinica. B2026

Activating protein kinases to treat diseases: Current understanding and future challenges.

Peng Jin, Minru Liao, Huidi Liu, Kun Huang, Leilei Fu, Xin Jin

Abstract readReview
In one paragraph

Review in Acta pharmaceutica Sinica. B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Peng JinDepartment of Urology, Shengjing Hospital of China Medical University, China Medical University, Shenyang 110004, China.
Minru LiaoSichuan Engineering Research Center for Biomimetic Synthesis of Natural Drugs, School of Life Science and Engineering, Southwest Jiaotong University, Chengdu 610031, China.
Huidi LiuDepartment of Anus and Intestine Surgery, The First Hospital of China Medical University, China Medical University, Shenyang 110001, China.
Kun HuangDepartment of Ultrasound, The First Hospital of China Medical University, China Medical University, Shenyang 110001, China.
Leilei FuSichuan Engineering Research Center for Biomimetic Synthesis of Natural Drugs, School of Life Science and Engineering, Southwest Jiaotong University, Chengdu 610031, China.
Xin JinDepartment of Ultrasound, The First Hospital of China Medical University, China Medical University, Shenyang 110001, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Protein kinases, as one of the most important human enzymes, are signaling molecules that regulate almost all cell activities, including growth, cell division and metabolism. Dysfunction of these cellular pathways can lead to a variety of human diseases. Accumulating evidence on the down-regulation of key protein kinases in diseases has made a big progress. The down-regulation is related to cancer, heart disease, neurodegenerative diseases and other diseases. Thus, in this review, we defined the classifications of protein kinases and demonstrated the mechanisms of protein kinase activators in the treatment of human diseases, summarized the research progress of protein kinase activators, and further discussed the development progress of protein kinase activators in clinical stage. Accordingly, activation of protein kinases has become a crucial target for drug development. With the in-depth understanding of protein kinase functions and regulation mechanisms, the development of new protein kinase activators may continue to be a rapidly growing field, which will help to develop more accurate and effective targeted therapeutic strategies in the near future.

Indexed as

ActivatorClinical trialHuman diseaseProtein kinaseSerine/threonine specific protein kinaseSmall-molecule pharmacological agentTherapeutic strategyTyrosine protein kinase

Identifiers

PMID41685165
PMCPMC12891856

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.